Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
NCT ID: NCT07171528
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
80 participants
INTERVENTIONAL
2025-09-10
2033-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer
NCT05827523
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
NCT01611766
Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
NCT00006356
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
NCT06292286
RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)
NCT07295132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\[Secondary Objectives\]
1. To compare the overall survival (OS) and cancer-specific survival (CSS) between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy.
2. To evaluate the adverse events between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy.
3. To assess the quality of life (QoL) between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy.
4. To investigate the prognostic role of the CA-125 KELIM model in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy.
5. To perform a cost-effectiveness analysis of the CRS group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No-Secondary Cytoreductive Surgery
* Secondary cytoreductive surgery in this study will be performed in patients who have undergone 3 cycles of chemotherapy and shown a response (Complete response, partial response, or stable disease).
* The chemotherapy regimen used before and after the intervention will be the same. Chemotherapy for patients with progressive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that recurs at least 6 months after platinum-based chemotherapy will be used.
* Both the CRS group and the control group will receive adjuvant chemotherapy for 3-6 cycles after enrollment.
* The following chemotherapy regimens are allowed and correspond to the standard treatments for platinum-sensitive recurrent ovarian cancer:
* Carboplatin/Paclitaxel ± Bevacizumab
* Carboplatin/Liposomal Doxorubicin ± Bevacizumab
* Carboplatin/Gemcitabine ± Bevacizumab
* Carboplatin/Topotecan
* Cisplatin/Topotecan
* Carboplatin/Docetaxel
* Cisplatin/Docetaxel
No interventions assigned to this group
Secondary Cytoreductive Surgery
Surgery will only be performed in patients assigned to the experimental arm of the study.
The goal of secondary cytoreductive surgery is to achieve complete tumor reduction by removing all visible residual tumors (Complete cytoreduction with no macroscopic residual disease), and this effort should be the top priority.
Secondary Cytoreductive Surgery
Surgery will only be performed in patients assigned to the experimental arm of the study.
The goal of secondary cytoreductive surgery is to achieve complete tumor reduction by removing all visible residual tumors (Complete cytoreduction with no macroscopic residual disease), and this effort should be the top priority.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Secondary Cytoreductive Surgery
Surgery will only be performed in patients assigned to the experimental arm of the study.
The goal of secondary cytoreductive surgery is to achieve complete tumor reduction by removing all visible residual tumors (Complete cytoreduction with no macroscopic residual disease), and this effort should be the top priority.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with recurrent ovarian cancer who have received platinum-based chemotherapy (3 or 4 cycles) and were deemed unsuitable for secondary cytoreductive surgery due to a negative AGO score according to the DESKTOP-III trial.
3. Patients with recurrent ovarian cancer who have responded to chemotherapy (Complete Response, Partial Response, or Stable Disease).
4. The patient's disease must have recurred after platinum-based therapy, and be defined as platinum-sensitive, meaning progression occurred more than 6 months (180 days) after the last administration of platinum-based therapy.
5. Patients aged 19 years or older at the time of providing informed written consent.
6. Patients with an ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2 within 28 days prior to clinical trial allocation.
7. Women who are medically unable to conceive or, if of childbearing potential, must agree to follow contraception guidelines during the treatment period.
8. The participant (or their legally authorized representative) must provide informed written consent regarding the trial.
9. The participant may consent to the secondary use of clinical information for future biomedical research. However, refusal to share clinical information for future research does not affect participation in the main trial.
10. The participant must have adequate organ function as defined in the table below. Specimens must be collected within 28 days.
1\) Adequate bone marrow function defined as
* White Blood Cell (WBC)≥ 2,500/㎕
* Platelet (PLT)≥ 100,000/㎕
* Hemoglobin (H)≥ 8 g/dl (after correction in cases of simple iron-deficiency anemia) 2) Adequate renal function defined as
* Creatinine or Creatinine Clearance (Cr or CrCl) or Glomerular filtration rate (GFR) (GFR can also be used instead of Cr or CrCl)
* Creatinine ≤ 1.5 mg/dL or within 1.5 times the upper limit of normal (ULN)
* CrCl ≥ 30 mL/min or GFR-EPI ≥ 30 mL/min/1.73m² 3) Adequate liver function defined as
* Total Bilirubin≤ 1.5 x ULN
* AST (SGOT) and ALT (SGPT)≤ 2.5 x ULN (for patients with liver metastasis, ≤ 5.0 x ULN) 4) No Significant dysfunction in Heart, Lungs, etc.
* No abnormalities in preoperative pulmonary function tests, electrocardiograms (ECG), or chest X-rays.
* For patients with a history of cardiac or pulmonary diseases, a collaborative evaluation with cardiology or pulmonology must confirm that surgery is feasible.
ALT(SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase) AST(SGOT) = aspartate aminotransferase (serum glutamic oxaloacetic transaminase) GFR = glomerular filtration rate; ULN = upper limit of normal
Exclusion Criteria
2. Patients with recurrent ovarian cancer who are not suitable for platinum-based chemotherapy.
3. Patients over 80 years of age.
4. Patients with a clinically assessed life expectancy of less than 3 months.
5. Patients deemed unsuitable for secondary cytoreductive surgery due to clinical findings (e.g., severe adhesions, bowel obstruction, fistula, perforation, or other conditions making surgery infeasible).
6. Patients with inadequate, cardiac, pulmonary, hepatic, renal, or bone marrow function for surgery.
7. Patients with uncontrolled active infections.
8. Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), or those exhibiting features suggestive of MDS/AML.
9. Patients whose primary disease is an extra-abdominal condition that is expected to be a major cause of morbidity or mortality.
10. Patients with active central nervous system metastasis or carcinomatous meningitis. Patients with a history of brain metastasis must be radiologically stable.
11. Patients with infections requiring systemic treatment (parenteral administration of antibiotics for bacterial, antifungal, or antivirals).
12. Patients with uncontrolled active tuberculosis (TB) within one month before treatment initiation.
13. Patients with psychiatric disorders that may interfere with their ability to comply with the trial, including those diagnosed with mental illness or substance abuse disorders.
14. Female patients who have not undergone a hysterectomy and have a positive urine pregnancy test within 14 days prior to study allocation. For women of childbearing potential, even if the screening urine pregnancy test is negative, additional pregnancy tests may be conducted at the discretion of the investigator at the time of surgery or chemotherapy initiation Pregnancy tests are not required for women who have undergone hysterectomy or are otherwise confirmed to be infertile.
15. Patients who are currently breastfeeding.
16. Patients with a history of allogeneic tissue/solid organ transplantation, bone marrow transplantation, or dual umbilical cord blood transplantation.
17. Patients who, in the judgment of the principal investigator, are unlikely to comply with the trial procedures, restrictions, and requirements.
18. Patients currently enrolled in another clinical trial and receiving an investigational drugs or medical device, or those who have used any investigational drugs or device within 3 weeks prior to the first administration of the study treatment.
19. Patients who have entered the follow-up phase of a clinical trial may participate in this study only if at least 3 weeks have passed since their last use of an investigational drug or device.
19 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Center, Korea
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myong Cheol Lim, MD, PhD
Principal Researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center, Korea
Goyang-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCC2025-0092
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.